Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. - Piccart,M.J.; Bertelsen,K.; Stuart,G.; Cassidy,J.; Mangioni,C.; Simonsen,E.; James,K.; Kaye,S.; Vergote,I.; Blom,R.; Grimshaw,R.; Atkinson,R.; et al. (Int J Gynecol Cancer, 2003)